Taylor Morrison Announces Consent Solicitations

Taylor Morrison (TMHC) commenced consent solicitations to amend indentures for its 5.75% 2028 notes, 5.125% 2030 notes, and 5.75% 2032 notes in connection with its acquisition by Berkshire Hathaway. Holders can receive a $1.00 consent fee per $1,000 principal if requisite consents are obtained, the fee is paid in full, and the merger closes; Berkshire intends to unconditionally guarantee the notes post-closing but has no obligation to do so. The solicitations are subject to customary conditions and amendments won’t become operative until the stated conditions are met.

Analysis

This is primarily a credit-process event, not a fundamental read-through on housing demand. The real value transfer is from bondholder optionality to deal certainty: a small consent fee is usually enough to pull paper over the line, but it also signals the issuer wants the debt stack cleaned up before close. That tends to help the equity closing path, while leaving the unsecured notes with less covenant protection unless the sponsor guarantee actually materializes.

The market should not extrapolate Berkshire ownership into Berkshire credit. Until the merger closes and a guarantee is signed, TMHC debt still trades with standalone cyclical risk, plus a non-trivial break/extension risk if execution slips. In that sense, the most likely near-term move is modest spread tightening on successful consents, but the larger repricing only happens after definitive sponsor support is documented.

Over the next 1-3 months, the key catalyst is legal completion rather than operations; over 6-18 months, the question is whether the capital structure becomes meaningfully cheaper under Berkshire stewardship or simply becomes an event-debt relic. The thesis is falsified by failed consents, merger delay, or any language that reduces the probability of a real guarantee. If the notes fail to tighten after the next process milestone, the market is probably assigning more break risk than the press tone suggests.

Key Decisions for Investors

• Buy TMHC 2030/2032 notes on any post-consent weakness, targeting 25-50 bps spread tightening into closing; stop if merger timing slips or Berkshire guarantee language remains non-binding in final docs.
• For merger-arb exposure, own TMHC equity only on a wider-than-normal deal spread; this is a process trade, not a fundamentals trade, so don’t add aggressively before consent completion.
• Fade any move that prices TMHC unsecured debt like Berkshire paper before the merger closes; the guarantee is optional, so the risk premium should not fully disappear yet.
• Do not initiate a BRK.B position on this news alone; the transaction is too small to move Berkshire equity, and the better expression is in TMHC credit/event paper rather than the parent.